FDA Grants Approval for Propranolol Hydrochloride ANDA219165
The FDA's approval of PAI Holdings' ANDA for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the potential impact on existing propranolol products and adjust strategies accordingly.
Company
Beta-blocker
Asset
FDA
Indication
Cardiovascular / Beta-blocker
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's approval of PAI Holdings' ANDA for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the potential impact on existing propranolol products and adjust strategies accordingly.
Why it matters
The FDA's approval of PAI Holdings' ANDA for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the potential impact on existing propranolol products and adjust strategies accordingly.
What changed
Regulatory Approval
Analysis
The FDA has granted approval for the ANDA219165 application for Propranolol Hydrochloride submitted by PAI Holdings.
The FDA's approval of PAI Holdings' ANDA for Propranolol Hydrochloride introduces a generic competitor into the beta-blocker market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the potential impact on existing propranolol products and adjust strategies accordingly.
Monitor market entry timelines and pricing strategies from PAI Holdings and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.